Karuna Therapeutics, Inc. Stock News

These three biotech companies could be headed for a buyout soon.

While researching about Karuna Therapeutics Inc. ( KRTX , Financial), I liked what I read so I decided to take a small position in the Boston-based biopharmaceutical company. Here I will invoke a comm

Karuna Therapeutics (KRTX) is progressing well with its pipeline development. KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.

Though Karuna's (KRTX) earnings miss estimates, KRTX's lead candidate meets late-stage study goals as a potential treatment for adults with schizophrenia.

The biotech's psych med hit the mark in a late-stage trial.

Source: Bukhta Yurii / Shutterstock.com Karuna Therapeutics (NASDAQ: KRTX ) stock is rocketing higher on Monday thanks to results from its Phase 3 EMERGENT-2 trial. This trial covers the efficacy, saf

SVB Leerink initiated coverage on Karuna Therapeutics Inc (NASDAQ: KRTX) with an Outperform rating and a price target of $170. SVB notes that Karuna already has one positive schizophrenia study (E

One analyst is putting the odds at three to one that tests of a Karuna Therapeutics Inc. ( KRTX , Financial) schizophrenia drug will meet study objectives, paving the way to Food and Drug Administrati

Treatments for schizophrenia – a truly complex disease--are plagued with a high late-stage trial failure rate. Phase 3 KarXT results will be released this quarter. It will be a binary event.

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric a

Karuna Therapeutics' (KRTX) first-quarter 2022 earnings beat estimates. Due to lack of marketed products in its portfolio, KRTX did not record any revenues during the quarter.

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy

BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psy

According to an SEC filing , Karuna Therapeutics Inc (NASDAQ: KRTX ) is withdrawing its prior guidance for the timing of topline data for its Phase 3 EMERGENT-3 trial evaluating KarXT in schizophrenia. The Company had expected topline data from the EMERGENT-3 trial in 2H of 2022. At this time, the … Full story available on Benzinga.com